Therapeutic Antibodies for treating Non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is the most common lung cancer. There are three main types:

    • Adenocarcinoma is the most common type of NSCLC. It develops from cells that make mucus. It is more often found in the outer area of the lung. Although the main cause is still smoking, this type of NSCLC is more common in non-smokers.
    • Squamous cell carcinoma develops in the cells that line the airways. It is more often found in the main airways in the centre of the lungs.
    • Large cell lung cancer is a very uncommon type that usually starts in the centre of the lungs.

Antibodies that have been approved by the FDA or NICE for treatment of Non-small cell lung cancer:

    • Atezolizumab
    • Bevacizumab
    • Ramucirumab
    • Pembrolizumab
    • Durvalumab
    • Nivolumab
    • Necitumumab
    • Amivantamab
    • Sintilimab

Antibodies that have been approved by the FDA or NICE for combination treatment of Non-small cell lung cancer are:

    • Nivolumab and Ipilimumab

Antibodies that are in clinical trials for the treatment of Non-small cell lung cancer are:

    • Tiragolumab
    • Tusamitamab
    • M7824
    • Oleclumab

Antibodies that are in clinical trials for combined treatment of non-small cell lung cancer are:

    • Monalizumab and Durvalumab
    • Oleclumab and Durvalumab
    • Tiragolumab and Atezolizumab

Leave a Reply

Your email address will not be published. Required fields are marked *